FDA approves Takeda drug for blood cancer multiple myeloma
NEW YORK (AP) — The U.S. Food and Drug Administration says it approved another drug to treat a type of blood cancer called multiple myeloma.
The approved drug, called Ninlaro, is made by Japanese drug company Takeda Pharmaceutical Co. The FDA approved two other multiple myeloma treatments this year, one from Johnson & Johnson and the other from Novartis AG.
Ninlaro is to be used with two other drugs by patients who have already received at least one other drug therapy. The FDA says Ninlaro can slow the progression of the disease when other treatments fail. Patients taking Ninlaro lived nearly three months longer without the disease worsening than those taking other regimens.
The National Cancer Institute estimates that about 27,000 people will be diagnosed with multiple myeloma this year.